These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 650919)

  • 1. [Myeloproliferative disorders and blood platelet function].
    Uchino H
    Rinsho Ketsueki; 1978 Feb; 19(2):187. PubMed ID: 650919
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet function and thromboxane synthesis in myeloproliferative disorders.
    Zahavi M; Zahavi J
    Blood; 1993 Aug; 82(4):1377-8. PubMed ID: 8353296
    [No Abstract]   [Full Text] [Related]  

  • 3. [Blood platelet function in chronic myeloid-type diseases. I. Myeloproliferative diseases].
    Cieslar P; Matousová O
    Vnitr Lek; 1987 Nov; 33(11):998-1009. PubMed ID: 3439041
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
    Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
    Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood platelet changes in myeloproliferative disorders].
    D'Angelo G; Calvano D; Giardini C
    Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet function after busulphan in chronic myeloproliferative disorders.
    Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E
    Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet activation in myeloproliferative disorders.
    Cortelazzo S; Viero P; Barbui T
    Thromb Haemost; 1981 Jun; 45(3):211-3. PubMed ID: 6169172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The platelet defect in myeloproliferative disorder (author's transl)].
    Delobel J
    Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet function studies in myeloproliferative disorders.
    Pfliegler G; Boda Z; Udvardy M; Kiss A; Telek B; Pecze K; Nagy P; Rak K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):655-62. PubMed ID: 2435631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet abnormalities in myeloproliferative disorders.
    Holme S; Murphy S
    Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phospholipids and platelet procoagulant activity in myeloproliferative syndromes].
    Martínez E; César J; Navarro JL; Mercado A; Pardo A; García Avello A; García Frade J
    Sangre (Barc); 1985; 30(1):22-7. PubMed ID: 4039850
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adrenergic receptors of blood platelets].
    Lanza F; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1987; 29(6):407-24. PubMed ID: 2837727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis].
    Hochhaus A; Mindner K; Ostermann G; Höche D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):765-70. PubMed ID: 1713878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet factor 3 activity in myeloproliferative disorders as evaluation by a new simple method].
    Inceman S; Tangün Y
    Turk Tip Cemiy Mecm; 1970; 36(9):317-20. PubMed ID: 5524541
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
    Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
    Zuk E
    Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.